First published July 23, 2020.
Did an inhaled protein treatment really cut Covid-19 deaths by almost 80 per cent? Not quite. In July 2020 a small British trial reported that inhaled interferon beta, a drug code-named SNG001 and made by Southampton company Synairgen, lowered the odds of hospital patients becoming severely ill. The 79 per cent figure described that risk of getting worse, not the death rate. When the treatment was tested in a far larger trial, it did not deliver the clear benefit the first results had promised.
Here is what the early study actually found, why it caused so much excitement, and what happened next.
Kaye Flitney, one of the volunteers enrolled in the UK trial, pictured by the BBC when the first results were reported in July 2020.
What the 2020 trial reported
The phase 2 study ran in British hospitals from March 2020, in the first wave of the pandemic. Roughly a hundred adults admitted with Covid-19 were split into two groups of about fifty. One group breathed in interferon beta through a nebuliser, a device that turns liquid medicine into a fine mist; the other inhaled a placebo. Neither the patients nor the doctors knew who was getting what.
According to the topline results, patients on the drug were 79 per cent less likely to progress to severe disease, meaning they needed mechanical ventilation or died, than those on the placebo. They were also more likely to recover, reported less breathlessness and tended to leave hospital sooner. No deaths were reported among the patients who received the drug.
The trial was led by Tom Wilkinson, professor of respiratory medicine at the University of Southampton. He told the BBC that the team couldn't have expected much better results than these
.
Why a reduction in odds is not a cut in deaths
Headlines at the time, including the original version of this page, spoke of an 80 per cent fall in deaths. That went further than the data. The study measured a combined outcome, getting severely ill or dying, and expressed the difference as odds. With so few patients, a handful of people moving from one column to the other can swing a percentage enormously.
Small trials also come with wide margins of uncertainty. Independent scientists welcomed the result but urged caution until the full data were peer-reviewed. Naveed Sattar, professor of metabolic medicine at the University of Glasgow, who was not involved, said a 79 per cent drop could be a game changer
, while stressing that a larger trial was needed to know the true size of any benefit.
That advice proved wise. The detailed results were published in The Lancet Respiratory Medicine in November 2020 and confirmed the encouraging pilot findings, but a pilot result is a reason to run a big trial, not a replacement for one.
How interferon beta is supposed to work
Interferons are proteins the body releases when a virus invades. They act as an alarm, switching on defences inside nearby cells so the virus struggles to copy itself. Some research suggested that the coronavirus behind Covid-19 dampens this early interferon response, and that older people and those with lung disease may produce less of it in their airways.
The idea behind SNG001 was to deliver interferon beta straight to the lungs, where the virus does most of its damage, giving local defences a boost before the illness spirals. Synairgen had already been developing the inhaled form for asthma and chronic obstructive pulmonary disease, conditions in which colds and flu often trigger dangerous flare-ups.
Interferon beta itself is not new. Injected forms of interferon beta-1a have been used for years to treat relapsing multiple sclerosis, where they help to rebalance an overactive immune system and reduce relapses. That familiarity was part of the appeal in 2020: doctors already knew a lot about the drug's safety.
What the larger SPRINTER trial found
Synairgen moved on to SPRINTER, an international phase 3 trial that began in January 2021. It enrolled 623 adults in hospital with Covid-19 who needed extra oxygen; about half received inhaled SNG001 and half a placebo, on top of standard care.
In February 2022 the company announced that the trial had missed its main goals. Patients on the drug left hospital no sooner than those on the placebo, and they recovered at about the same pace. The key secondary measures did not reach statistical significance either:
- Progression to severe disease or death by day 35: 10.7 per cent with SNG001 against 14.7 per cent with placebo, a trend that could have arisen by chance.
- Deaths by day 35: 4.5 per cent against 5.4 per cent, again not a statistically meaningful gap.
- The drug was well tolerated, with fewer serious adverse events in the treatment group than in the placebo group.
Synairgen pointed out one big change since 2020. In the pilot, no patients had been on steroids; in SPRINTER, 87 per cent were already receiving corticosteroids such as dexamethasone when they joined. Steroids had become standard after the RECOVERY trial showed they save lives in patients needing oxygen, which left less room for any extra drug to show a difference.
The wider picture on interferon and Covid-19
Inhaled interferon was not the only version tested. The World Health Organization's Solidarity trial gave interferon beta-1a by injection to hospitalised patients and found that it did not reduce deaths compared with usual care. Results like these explain why interferon never joined the short list of proven hospital treatments, which came to include steroids, certain anti-inflammatory drugs and antivirals given early.
The story also shows how drug news reaches the public. Synairgen is listed on the London stock market, and its shares soared on the day of the first announcement. Listed companies must disclose information that could move their share price, so promising early results often appear in a press release long before a peer-reviewed paper, and before a larger trial has had the chance to confirm or overturn them.
How to read the next miracle-cure headline
Covid-19 produced a stream of headlines about breakthrough treatments, and many faded once bigger studies reported. A few questions help separate a real advance from an early hope:
- How many patients? A trial of about a hundred people can hint at an effect; it rarely proves one.
- What exactly was measured? A drop in the odds of getting worse is not the same as a drop in deaths.
- Has it been peer-reviewed and repeated? Press releases come first; replication is what counts.
- Who is announcing it? Company statements are legitimate, but they are written for investors as well as patients.
None of this means the 2020 trial was misleading. It was a carefully designed pilot that justified a bigger study, and that bigger study gave the answer. Anyone with questions about Covid-19 treatment for themselves or a relative should talk to a doctor.
On the same day these results came out, Oxford University reported early immune data for its vaccine, a reminder that 2020 was a year when hope and hard evidence often arrived together, and did not always agree.
Sources: BBC News, July 2020 (original report, photo and video); Synairgen: topline results from phase 3 SPRINTER trial (21 February 2022); Wikipedia: Synairgen; Wikipedia: Interferon beta-1a.

COMMENTS